BCN-CP01 clinical trials

A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This study is looking at a new treatment called BCN-CP01 for people with certain types of blood cancer (relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma) that have come back or not responded to previous treatments. It aims to see if the treatment is safe and if it helps patients get better.